Equillium (EQ) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Equillium

NasdaqCM•Healthcare•Biotechnology

$2.21-0.01(<0.01%)Market closed

Market Cap

$211.31M

P/B

3.8x

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

How this company scores

AverageMetricSide Score: 46/100

Strongest: Profitability (17/25); weakest: Growth (6/25).

Profitability17/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Long cash runwayInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 21.7x5y range 0.5x – 21.7x

Currently above its 12-quarter median.

P/B · 3.8x5y range 0.8x – 3.8x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $211.31M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-19.30M
TTM Op. Income: $-19.30M
Q. Op. Income: $-5.16M
TTM Net Income: $-18.01M
Q. Net Income: $-4.69M
EPS: $-0.04
Shares Out.: $111.81M

$0 in TTM revenue declined 100.0% YoY, reaching $0 last quarter. TTM EBITDA of $-19.30M and TTM operating income of $-19.30M show growth is flowing through to the bottom line. However, net income is negative at $18.01M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 100% — a steady trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -515500000.0%
Net Margin: -469300000.0%

Op. margin of -515500000.0% is up 107300000.0% YoY — cost efficiency is improving. Net margin at -469300000.0% Over the past year, operating margin is up 17% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 3.8x

P/S of 0.0x and P/B of 3.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $58.67M
Cash: $57.16M
Long-Term Debt: N/A
Book Value: $56.02M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-4.11M
TTM Free Cash Flow: $-20.09M
FCF Margin: N/A
FCF / Net Income: 1.1

TTM FCF of $-20.09M on $-4.11M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 9% — a weakening trend.